ITEM 5.07 Submission of Matters to a Vote of Security Holders.
OnMay 25, 2023 ,Soleno Therapeutics, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders. Of the 8,168,788 shares of common stock outstanding as ofApril 12, 2023 , the record date, 6,095,961 shares of common stock were represented at the meeting in person or by proxy, constituting approximately 74.63% of the outstanding shares of common stock entitled to vote and constituting a quorum for the transaction of business.
The stockholders of the Company voted on the following items at the Meeting:
1. To elect two Class II directors to serve until the 2026 Annual Meeting of
stockholders or until their respective successors are duly elected and qualified;
2. To ratify the appointment of
registered public accounting firm for the fiscal year ending
2023; 3. To approve, on any advisory basis, the compensation of the Named Executive Officers of the Company;
4. To approve, on any advisory basis, the frequency of stockholder votes on
the compensation of the Named Executive Officers of the Company; 5. To approve the amended and restated 2014 Equity Incentive Plan; and
6. To approve the issuance of the shares upon the exercise of the warrants
sold in the private placement on
Proposal One - Election of Directors
The table below presents the voting results of the election of the two Class II directors to the Company's Board of Directors by the Company's stockholders: Nominee Votes For Votes Withheld Percent of Voted Broker Non-Votes Ernest Mario 3,950,528 195,740 64.8 % 1,949,693 Birgitte Volck 4,066,365 79,903 66.7 % 1,949,693
Proposal Two - Ratification of Appointment of Independent Registered Public Accounting Firm
The Company's stockholders ratified the appointment of
Votes For Votes Against Abstentions Broker Non-Votes 5,977,682 113,718 4,561
0
Proposal Three - Approval of Named Executive Compensation, on an Advisory Basis
The Company's stockholders approved the Named Executive Officer compensation by the following votes:
Votes For Votes Against Abstentions Broker Non-Votes 4,019,358 111,424 15,486 1,949,693
Proposal Four - Approval of Frequency of Stockholder Votes on Named Executive Officer Compensation, on an Advisory Basis
The Company's stockholders approved "every three years" for the frequency of stockholder votes on Named Executive Officer compensation by the following votes:
Votes for Every Votes for Every Votes For Every 3 Years 2 Years 1 Years
Abstentions Broker Non-Votes
2,234,536 18,934 1,865,518 27,280
1,949,693
--------------------------------------------------------------------------------
Proposal Five - Approval of Amended and Restated 2014 Equity Incentive Plan
The Company's stockholders approved the Company's Amended and Restated 2014 Equity Incentive Plan, by the following votes:
Votes For Votes Against Abstentions Broker Non-Votes 3,874,198 254,424 17,646 1,949,693
The Company's Board of Directors (the "Board") has considered the outcome of this non-binding advisory vote and has accepted the stockholders' non-binding advisory vote on the three-year frequency of say-on-pay votes. Accordingly, the Company will place a non-binding advisory vote on the Company's executive compensation on the agenda for the 2026 annual stockholders meeting.
Proposal Six - Approval of Private Placement
The Company's stockholders approved the issuance of the shares upon the exercise of the warrants sold in the private placement onMay 8, 2023 , by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 4,003,720 132,021 10,527 1,949,693
--------------------------------------------------------------------------------
© Edgar Online, source